摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(4-氯苯基)硫代]噻吩-3-苯甲酸甲酯 | 175202-88-7

中文名称
4-[(4-氯苯基)硫代]噻吩-3-苯甲酸甲酯
中文别名
——
英文名称
4-(4-chlorophenylsulfanyl)thiophene-3-carboxylic acid methyl ester
英文别名
Methyl 4-[(4-chlorophenyl)thio]thiophene-3-carboxylate;methyl 4-(4-chlorophenyl)sulfanylthiophene-3-carboxylate
4-[(4-氯苯基)硫代]噻吩-3-苯甲酸甲酯化学式
CAS
175202-88-7
化学式
C12H9ClO2S2
mdl
——
分子量
284.787
InChiKey
NJFQCQSYIJGCNG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    392.5±37.0 °C(Predicted)
  • 密度:
    1.41±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    79.8
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 安全说明:
    S24/25
  • 海关编码:
    2934999090

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    [EN] INDOLES AND THEIR THERAPEUTIC USE
    [FR] INDOLES ET LEUR UTILISATION THÉRAPEUTIQUE
    摘要:
    式(I)的化合物是CRTH2受体的配体,尤其适用于治疗炎症性疾病。其中,X为-SO2-或*-SO2NR3-,其中带有星号的键连接到Ar1;R1为氢、氟、氯、氰基或三氟甲基;R2为氢、氟或氯;R3为氢、C1-C8烷基或C3-C7环烷基;Ar1为苯基或选自呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、吡啶基、吡嗪基、嘧啶基和哒嗪基的5或6元杂芳基,其中苯基或杂芳基可任选地被一个或多个独立选自氟、氯、氰基、C3-C7环烷基、-O(C1-C4烷基)或C1-C6烷基的取代基取代,后两个基团可任选地被一个或多个氟原子取代;Ar2为苯基或选自吡咯基、呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、吡啶基、吡嗪基、嘧啶基和哒嗪基的5或6元杂芳基,其中苯基或杂芳基可任选地被一个或多个独立选自氟、氯、氰基、C3-C7环烷基、-O(C1-C4烷基)或C1-C6烷基的取代基取代,后两个基团可任选地被一个或多个氟原子取代。
    公开号:
    WO2009077728A1
点击查看最新优质反应信息

文献信息

  • Indoles and Their Therapeutic Use
    申请人:Hynd George
    公开号:US20110071175A1
    公开(公告)日:2011-03-24
    Compound of formula (I) are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is —SO 2 — or *—SO 2 NR 3 — wherein the bond marked with an asterisk is attached to Ar 1 ; R 1 is hydrogen, fluoro, chloro, CN or CF 3 ; R 2 is hydrogen, fluoro or chloro; R 3 is hydrogen, C 1 C 8 alkyl or C 3 -C 7 cycloalkyl; Ar 1 is phenyl or a 5- or 6-membered heteroaryl group selected from furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C 3 -C 7 cycloalkyl, —O(C 1 -C 4 alkyl) or C 1 C 6 alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and Ar 2 is phenyl or 5- or 6-membered heteroaryl group selected from pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C 3 -C 3 -C 7 cycloalkyl, —O(C 1 -C 4 alkyl) or C 1 C 6 alkyl, the latter two groups being optionally substituted by one or more fluoro atoms.
    (I)的化合物是CRTH2受体的配体,可用于治疗炎症病症等。其中X为—SO2—或*—SO2NR3—,其中用星号标记的键连接到Ar1;R1为氢、氟、氯、氰或三氟甲基;R2为氢、氟或氯;R3为氢、C1-C8烷基或C3-C7环烷基;Ar1为苯基或从呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、吡啶基、吡嗪基、嘧啶基和吡嗪基中选择的5-或6-成员杂芳基,其中苯基或杂芳基可选地被一个或多个取代基独立地选择自氟、氯、氰、C3-C7环烷基、—O(C1-C4烷基)或C1-C6烷基,后两个基可选地被一个或多个氟原子取代;Ar2为苯基或从吡咯基、呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、吡啶基、吡嗪基、嘧啶基和吡嗪基中选择的5-或6-成员杂芳基,其中苯基或杂芳基可选地被一个或多个取代基独立地选择自氟、氯、氰、C3-C7环烷基、—O(C1-C4烷基)或C1-C6烷基,后两个基可选地被一个或多个氟原子取代。
  • Indoles and their therapeutic use
    申请人:Hynd George
    公开号:US08394836B2
    公开(公告)日:2013-03-12
    Compound of formula (I) are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is —SO2— or *—SO2NR3— wherein the bond marked with an asterisk is attached to Ar1; R1 is hydrogen, fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; R3 is hydrogen, C1C8alkyl or C3-C7cycloalkyl; Ar1 is phenyl or a 5- or 6-membered heteroaryl group selected from furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3-C7cycloalkyl, —O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and Ar2 is phenyl or 5- or 6-membered heteroaryl group selected from pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3-C3-C7cycloalkyl, —O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms.
    式(I)的化合物是CRTH2受体的配体,可用于治疗炎症疾病等。其中,X为—SO2—或*—SO2NR3—,其中带有星号的键连接到Ar1;R1为氢、氟、氯、CN或CF3;R2为氢、氟或氯;R3为氢、C1C8烷基或C3-C7环烷基;Ar1为苯基或选择自呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异硫唑基、吡啶基、吡嗪基、嘧啶基和吡咯基的5-或6-成员杂环基,其中苯基或杂环基可以选择性地被一个或多个取代基独立地选择自氟、氯、CN、C3-C7环烷基、—O(C1-C4烷基)或C1C6烷基所取代,后两个基可以选择性地被一个或多个氟原子取代;Ar2为苯基或选择自吡咯基、呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异硫唑基、吡啶基、吡嗪基、嘧啶基和吡咯基的5-或6-成员杂环基,其中苯基或杂环基可以选择性地被一个或多个取代基独立地选择自氟、氯、CN、C3-C7环烷基、—O(C1-C4烷基)或C1C6烷基所取代,后两个基可以选择性地被一个或多个氟原子取代。
  • INDOLES AND THEIR THERAPEUTIC USE
    申请人:PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
    公开号:US20130225617A1
    公开(公告)日:2013-08-29
    Compounds of the invention are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions.
    本发明的化合物是CRTH2受体的配体,可用于治疗炎症等病症。
  • US8394836B2
    申请人:——
    公开号:US8394836B2
    公开(公告)日:2013-03-12
  • [EN] INDOLES AND THEIR THERAPEUTIC USE<br/>[FR] INDOLES ET LEUR UTILISATION THÉRAPEUTIQUE
    申请人:ARGENTA DISCOVERY LTD
    公开号:WO2009077728A1
    公开(公告)日:2009-06-25
    Compound of formula (I) are are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is -SO2- or *-SO2NR3- wherein the bond marked with an asterisk is attached to Ar1; R1 is hydrogen, fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; R3 is hydrogen, C1C8alkyl or C3-C7cycloalkyl; Ar1 is phenyl or a 5- or 6-membered heteroaryl group selected from furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3- C7cycloalkyl, -O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and Ar2 is phenyl or 5- or 6-membered heteroaryl group selected from pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3- C3- C7cycloalkyl, -O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms.
    式(I)的化合物是CRTH2受体的配体,尤其适用于治疗炎症性疾病。其中,X为-SO2-或*-SO2NR3-,其中带有星号的键连接到Ar1;R1为氢、氟、氯、氰基或三氟甲基;R2为氢、氟或氯;R3为氢、C1-C8烷基或C3-C7环烷基;Ar1为苯基或选自呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、吡啶基、吡嗪基、嘧啶基和哒嗪基的5或6元杂芳基,其中苯基或杂芳基可任选地被一个或多个独立选自氟、氯、氰基、C3-C7环烷基、-O(C1-C4烷基)或C1-C6烷基的取代基取代,后两个基团可任选地被一个或多个氟原子取代;Ar2为苯基或选自吡咯基、呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、吡啶基、吡嗪基、嘧啶基和哒嗪基的5或6元杂芳基,其中苯基或杂芳基可任选地被一个或多个独立选自氟、氯、氰基、C3-C7环烷基、-O(C1-C4烷基)或C1-C6烷基的取代基取代,后两个基团可任选地被一个或多个氟原子取代。
查看更多